Skip to content

Accuracy for Predicting Deep Submucosal Invasion

Diagnostic Accuracy of Deep Submucosal Invasion: White Light Endoscopy vs Invasive Pattern Based on NBI/BLI ± Chromoendoscopy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03748667
Acronym
NBIBLI
Enrollment
426
Registered
2018-11-21
Start date
2018-12-01
Completion date
2022-10-30
Last updated
2023-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, Colorectal Polyp

Keywords

Endoscopy, Colonoscopy, Invasive pattern, Polypectomy, NBI, BLI, Deep submucosal invasion, JNET, Kudo pit pattern

Brief summary

The main aim of this study is to determine whether the assessment of the invasive pattern based on NBI with dual focus/magnification or BLI with magnification ± chromoendoscopy (NBI+CE) for predicting deep invasion is significantly more accurate than the assessment based on white light endoscopy (WLE), carried out by trained endoscopists.

Detailed description

A video with the lesion assessment, without any data on the patient, will be recorded in a device connected to the processor provided by the Principal Investigator. The name of the file will be the record ID. All the lesions will be tested by the same endoscopist in vivo and an assistant will fulfill the data collection sheet during the colonoscopy. First, the lesions will be cleaned and observed in a stable position. Size, location, morphology, demarcated areas, and gross morphological malignant features will be evaluated. Based on these WLE characteristics, a deep invasion prediction will be performed (control test). Second, the lesion will be assessed using NBI with near focus or magnification or BLI with magnification. A second cleaning with pronase (or N-acetylcysteine if pronase is not available) if the surface cannot be clearly observed because of the presence of mucus or if crystal violet is going to be used. Crystal violet 0.05% will be used in case of polyps type 2B in the JNET classification or lesions with a demarcated area. A non-traumatic catheter (or spray catheter) will be used to spray the crystal violet over the lesion. A final prediction of deep invasion will be performed for NBI or BLI ± CE (test evaluated). The use of a cap to observe the bottom of the lesion, fix the lesion close to the endoscope or to observe the lesion underwater immersion is strongly recommended. The resection technique will be decided upon according to the local experience. In case of endoscopy resection (cold snare, EMR, ESD, full thickness), lesions will be removed via the anus (not through the endoscopy channel) in order to preserve their integrity. Although EMR is performed, if possible, lesions will be referred to the pathologist well oriented and pinned out on a cork based, as is standard procedure in ESD. In order to ensure that endoscopic assessment is performed before the histology evaluation, both diagnostic assessments (control test and test evaluated) will be recorded on the REDCap database on the day of the colonoscopy. REDCap records the time and date of all changes in the variables' results. The remaining variables (demographic data, etc.) will be recorded on the data collection sheet and copied later into REDCap. Videos of the lesion assessments will be sent to the Principal Investigator. Centralized visualization will be conducted to detect protocol violations and to exclude lesions from the study. A blinded histology assessment will be conducted by the local pathologist and if a carcinoma with submucosal invasion is diagnosed, histology slides will be referred for an additional blinded and centralized histology evaluation at the end of the study. Pathologists participating in the histological phase will assess all the slides with submucosal invasion and will collect the histological factors associated with lymph node metastasis. Finally, investigators participating in the translational phase will refer paraffin blocks of 10 lesions of each JNET category (2A, 2B and 3) for genetic tests (sequencing of a panel of 45 genes and analysis of alterations in the number of copies of the genome).

Interventions

Subjective endoscopic assessment of deep submucosal invasion based on the presence of gross morphological malignant features, morphology and size.

DIAGNOSTIC_TESTNBI/BLI +/- chromoendoscopy (NBIBLI +/- CE)

Endoscopic assessment of deep submucosal invasion with NBI and dual focus/magnification or BLI and magnification. In the case of demarcated areas or JNET 2B, Kudo pit pattern assessment with crystal violet will be performed.

Sponsors

Hospital Universitario La Fe
CollaboratorOTHER
Hospital Clínico Universitario Lozano Blesa
CollaboratorOTHER
University of North Carolina, Chapel Hill
CollaboratorOTHER
Hospital Clinic of Barcelona
CollaboratorOTHER
National Cancer Center, Japan
CollaboratorOTHER_GOV
Germans Trias i Pujol Hospital
CollaboratorOTHER
Hospital Universitario 12 de Octubre
CollaboratorOTHER
Hospital Universitario Ramon y Cajal
CollaboratorOTHER
San Francisco Veterans Affairs Medical Center
CollaboratorFED
Hospital Universitario Virgen de la Arrixaca
CollaboratorOTHER
Hospital Comarcal de Alcañiz
CollaboratorUNKNOWN
Centro Medico Teknon
CollaboratorOTHER
Althaia Xarxa Assistencial Universitària de Manresa
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Non-pedunculated type 0 lesions in Paris classification (not obvious cancers) * Lesions larger than 10 mm

Exclusion criteria

are: * Lesions assessed as JNET 1 by the endoscopist or serrated by the pathologist * Previous biopsy or resection attempt * Previous CT, MR or USE * Unavailable histology * Inflammatory bowel disease * Informed consent not obtained * Protocol violation

Design outcomes

Primary

MeasureTime frameDescription
The presence or absence of deep invasion according to the control test (WLE)One dayDeep invasion will subjectively be diagnosed based on the presence of gross morphological malignant features, morphology and size. No single malignant feature, specific morphology or size is required. The importance given to each criterion and the final diagnosis of deep invasion is based on the personal experience of the endoscopist.
The presence or absence of deep invasion according to the test evaluated (NBI/BLI +/- CE)One dayDeep invasion will be diagnosed in case of: * JNET type 3 or * JNET 2B + Kudo Vn pit pattern or * JNET 2B and Kudo Vi pit pattern fulfilling all the following criteria: severe Kudo Vi pit pattern + presence of a demarcated area + size (demarcated area) \>6 mm for PG or 3 mm for NPG.
The presence or absence of deep invasion according to the gold standard (histology)One dayDeep invasion will be diagnosed if sm invasion ≥1000 μm is measured according to the Japanese guidelines by the central pathologists.

Secondary

MeasureTime frameDescription
Presence of any genetic mutationsone daySequencing of a panel of colorectal cancer genes: the 45 genes will be sequenced frequently mutated in colorectal cancer, through the protocols established in the center Executor: APC, TP53, FBXW7, SOX9, ATM, SMAD4, KRAS, PIK3CA, AMER1, FAT4, ARID1A, BRAF, NRAS, CTNNB1, TCF7L2, ERBB2, MET, EGFR, HRAS, SETD2, DLC1, CDKN2A, PTEN, ARID2, FAT1, POLE, POLD1, NOTCH1, BRCA2, LRP1B, KMT2C, KMT2D, DAPK1, CSMD1, MUC16, ADAMTS15, SYNE1, PCLO, ZFHX4, RYR3, RYR2, RELN, IRS2, GNAS, DMBT1.
Number of genome copies using SNP-arraysone dayNumber of copies using SNP-arrays.

Countries

Japan, Spain, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026